Retinal Vein Occlusion clinical trials

Explore recruiting retinal vein occlusion clinical trials.

Recruiting retinal vein occlusion studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Retinal Vein Occlusion trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Spontaneous Retinal Arterial Pulsations (SRAPs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVOs) in patients treated or not with intravitreal injections of aflibercept

France

Therapeutic exploratory (Phase II) EU CTIS Study details

(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion

France, Slovakia, Portugal, Lithuania, Hungary, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-term need of Ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion (CoRaLa II trial)

Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK)

Romania, Bulgaria, Germany, Spain, Czechia, France +6 more

Phase III and phase IV (Integrated) EU CTIS Study details

An open-label, single group, single-dose clinical study to evaluate the usability of the pre-filled syringe (PFS) of SB11 in trial participants with Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), or Myopic Choroidal Neovascularization (mCNV)

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Retinal Vein Occlusion trials by city

Retinal Vein Occlusion in Toronto Retinal Vein Occlusion in Vancouver Retinal Vein Occlusion in Montreal Retinal Vein Occlusion in Calgary Retinal Vein Occlusion in Edmonton Retinal Vein Occlusion in Ottawa Retinal Vein Occlusion in Winnipeg Retinal Vein Occlusion in Quebec City Retinal Vein Occlusion in Hamilton Retinal Vein Occlusion in Kitchener Retinal Vein Occlusion in London Retinal Vein Occlusion in Halifax Retinal Vein Occlusion in New York Retinal Vein Occlusion in Los Angeles Retinal Vein Occlusion in Chicago Retinal Vein Occlusion in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease